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Tumor microenvironment-targeted nanoparticles
loaded with bortezomib and ROCK inhibitor
improve efﬁcacy in multiple myeloma
Cinzia Federico1,7, Kinan Alhallak 1,2,7, Jennifer Sun1,2, Kathleen Duncan3, Feda Azab1, Gail P. Sudlow3,
Pilar de la Puente1, Barbara Muz1, Vaishali Kapoor 1, Luna Zhang1,2, Fangzheng Yuan1,4, Matea Markovic 1,4,
Joseph Kotsybar1,4, Katherine Wasden1, Nicole Guenthner 1, Shannon Gurley1, Justin King5, Daniel Kohnen5,
Noha N. Salama 4,6, Dinesh Thotala1, Dennis E. Hallahan1, Ravi Vij5, John F. DiPersio5, Samuel Achilefu 2,3 &
Abdel Kareem Azab 1,2 ✉

Drug resistance and dose-limiting toxicities are signiﬁcant barriers for treatment of multiple
myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug
resistance in MM. Drug delivery with targeted nanoparticles have been shown to improve
speciﬁcity and efﬁcacy and reduce toxicity. We aim to improve treatments for MM by (1)
using nanoparticle delivery to enhance efﬁcacy and reduce toxicity; (2) targeting the tumorassociated endothelium for speciﬁc delivery of the cargo to the tumor area, and (3) synchronizing the delivery of chemotherapy (bortezomib; BTZ) and BMME-disrupting agents
(ROCK inhibitor) to overcome BMME-induced drug resistance. We ﬁnd that targeting the
BMME with P-selectin glycoprotein ligand-1 (PSGL-1)-targeted BTZ and ROCK inhibitorloaded liposomes is more effective than free drugs, non-targeted liposomes, and single-agent
controls and reduces severe BTZ-associated side effects. These results support the use of
PSGL-1-targeted multi-drug and even non-targeted liposomal BTZ formulations for the
enhancement of patient outcome in MM.
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M

ultiple myeloma (MM), the second most common
hematological malignancy1, is characterized by the
neoplastic transformation and growth of plasma cells
within the bone marrow (BM). The advent of several therapeutic
agents, including proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), has signiﬁcantly improved the outcomes
of MM treatment. However, almost all MM patients become
refractory to treatment and relapse due to de novo drug resistance2–4.
We have previously studied the role of the BM microenvironment (BMME) in the development of drug resistance in
MM. We found that direct interaction of MM cells with the BM
stroma, endothelial cells (ECs), and extracellular matrix, as well as
the cytokines and chemokines present in the BM milieu, induced
drug resistance in MM cells5–8. Disruption of the interaction
between MM cells and the BMME via inhibition of CXCR4 or
selectins sensitized MM to therapy in vitro and in vivo7–9. The
interaction of MM with stromal and ECs in the BMME is promoted through a signaling cascade that involves Rho guanosine
triphosphatases and inhibition of their downstream targets, such
as Rho kinase (ROCK), results in the abrogation of the
MM–BMME interaction5. The combined use of chemotherapeutic and BMME-disrupting agents, such as bortezomib (BTZ)
and a ROCK inhibitor, respectively, is an unexplored treatment
approach for MM.
Serious side effects are the primary limitation for effective use
of chemotherapies such as PIs and IMiDs in MM. Treatment with
PIs is limited by their neurotoxicity, especially in the peripheral
nerves, which leads to sensory axonal neuropathy10,11. Therefore,
MM treatment strategies that speciﬁcally target MM cells,
increase treatment efﬁcacy, and reduce off-tumor side effects are
urgently needed.
Recent efforts have focused on shifting from cytotoxic and
non-speciﬁc chemotherapies to molecularly targeted and
rationally-designed therapies that exhibit greater efﬁcacy and
fewer side effects12. Several studies have used nanoparticles for
treatment of MM; however, most of these treatments were nontargeted, which led to considerable pharmacokinetic and pharmacodynamic disadvantages, including lack of speciﬁcity and
dependency on the enhanced permeability and retention (EPR)
effect13. We have recently shown that delivery of a PI, such as
BTZ, in a CD38-targeted cross-linked chitosan nanoparticle,
signiﬁcantly reduced the toxicity proﬁle of BTZ in vivo14. The
anti-CD38 chitosan nanoparticles facilitated endocytosismediated uptake of CD38, which enhanced BTZ’s proteasomeinhibitory activity and speciﬁcity and resulted in a low toxicity
proﬁle to represent a promising therapy for MM. Despite this
effect, the tumors eventually relapsed, most likely due to BMMEinduced drug resistance.
In this study, we develop a P-selectin glycoprotein ligand-1
(PSGL-1)-decorated liposomes, targeting tumor-associated ECs,
loaded with BTZ and BMME-disrupting ROCK inhibitor Y27632
to promote therapeutic efﬁcacy and overcome TME-induced
resistance. We ﬁnd that targeting the BMME with PSGL-1targeted BTZ and ROCK inhibitor-loaded liposomes is more
effective than free drugs, non-targeted liposomes, and singleagent controls, and reduces BTZ-associated side effects, for the
treatment of MM.
Results
Expression of P-selectin on MM-associated ECs in humans,
in vivo, and in vitro. Using ﬂow cytometry, we investigated
the expression of P-selectin in healthy and tumor-associated
ECs, in primary healthy and MM patient BM samples, respectively. The gating strategy is shown in Supplementary Fig. 1. We
2

demonstrated that expression of P-selectin was 6-fold higher on
ECs from the BM of patients who had newly diagnosed or
relapsed MM compared to ECs from the BM of healthy donors
(Fig. 1a). Similarly, we tested the expression of P-selectin in mice
in ECs isolated from BM of healthy and MM-bearing, using ﬂow
cytometry. We found a 2.5-fold higher increase of P-selectin
expression on ECs from the BM of MM-bearing mice compared
to ECs from healthy mice (Fig. 1b). We also investigated the
expression of P-selectin on ECs (VEGFR-2+ cells) in the femurs
of healthy and MM-bearing mice via immunoﬂuorescence. The
presence and level of P-selectin expression co-localized with
VEGFR-2+ ECs was greater on ECs in the BM of MM-bearing
mice compared with healthy mice (Fig. 1c).
To better simulate the BM niche, we developed the 3D tissueengineered bone marrow (3DTEBM) using BM plasma derived
from MM patients which is shown in Supplementary Fig. 2a15.
Human umbilical vein ECs (HUVECs, cyan) were plated on top
of the 3DTEBM; stromal (red) and MM (green) cells were plated
inside the 3DTEBM matrix (Supplementary Fig. 2b). The MM
cells were dispersed throughout the scaffold whereas the stromal
cells coalesced toward the bottom of the culture, biomimicking
the BM niche.
Next, we examined the expression of P-selectin in HUVECs
cultured alone or with MM cells in traditional 2D culture
(Matrigel) or in the 3DTEBM. In the 3DTEBM, we observed a 6fold increase in P-selectin expression on the HUVECs cultured
with MM (MM.1S, H929, or OPM-2) compared to ECs alone
(Fig. 1d). In traditional 2D cultures, P-selectin expression did not
signiﬁcantly increase even when co-cultured with MM cell lines.
We also investigated whether or not P-selectin expression
increased when co-cultured with non-malignant cells. In Fig. 1e,
we found that, unlike the co-culture of ECs with MM, co-culture
of ECs and PBMCs did not increase in P-selectin expression in
ECs. In addition, HUVECs were plated on Matrigel alone (2D) or
on top of the 3DTEBM with and without MM. We saw that the
ECs formed signiﬁcantly more tube-like features when cocultured with MM in the 3DTEBM, compared to ECs alone
without MM cells or in 2D conditions (Fig. 1f and g).
Binding of PSGL-1-targeted liposomes to P-selectin and MMassociated ECs in vitro and in vivo. Next, we developed PSGL-1targeted liposomes to target the overexpressed P-selectin on MMassociated endothelium; a schematic of these liposomes is shown
in Fig. 2a. The physical characteristics of the PSGL-1-targeted and
non-targeted liposomes are summarized in Supplementary
Table 1 and cryogenic transmission electron microscopy (cryoTEM) images are shown in Fig. 2b. To evaluate the afﬁnity
of PSGL-1-targeted liposomes for P-selectin, we assessed the
binding of the liposomes to P-selectin. The successful immobilization of P-selectin to the surface plasmon resonance sensor chip
is shown in Supplementary Fig. 3. We found that, compared to
non-targeted, PSGL-1-targeted liposomes showed an 8-fold
increase in binding to recombinant P-selectin (Fig. 2c). We also
tested the binding of the PSGL-1- and non-targeted liposomes to
naive and tumor-associated ECs in the 3DTEBM described in
Fig. 1. We found that the non-targeted liposomes exhibited
negligible binding to the endothelium; while the PSGL-1-targeted
liposomes had signiﬁcantly higher binding (7-fold) to the tumorassociated endothelium compared to the naive endothelium
(Fig. 2d). In addition, we tested the binding of the PSGL-1targeted and non-targeted liposomes to tumor-associated ECs in
the BM of MM-bearing mice. We found that PSGL-1-targeted
liposomes exhibited signiﬁcantly greater binding to the MMassociated endothelium compared to non-targeted liposomes
(Fig. 2e).
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Targeting the tumor microenvironment with PSGL-1 in vivo.
Following the successful targeting of the tumor microenvironment in Fig. 2e, we subsequently injected MM.1S subcutaneously
in NCG mice. Non-targeted and PSGL-1-targeted liposomes
colored with DiO and DiD, respectively, were mixed and injected
intravenously following tumor propagation. As time progressed,

we observed a higher accumulation of the PSGL-1-targeted
liposomes in the tumor area compared to non-targeted after 24 h
(Fig. 3a). There is a signiﬁcantly higher presence of PSGL-1targeted liposomes after 24 h as shown quantitatively in Fig. 3b.
Following 24 h, we extracted the organs of these mice and
assessed the percent accumulation in each organ 24 h post-
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Fig. 1 P-selectin is overexpressed on MM-associated endothelium. a P-selectin expression on endothelial cells (ECs) of healthy and (multiple myeloma)
MM subjects (p value = 0.026; n = 6 samples examined over one independent experiment). Data presented here are deﬁned as mean values +/− SEM.
b Expression of P-selectin on the BM endothelium of healthy and MM-inoculated mice (p value < 0.001; n = 3 samples examined over one independent
experiment). c Immunoﬂuorescence of VEGFR-2 and P-selectin on sections from BM of healthy and MM-inoculated mice. d P-selectin expression in ECs
cultured alone or with MM cells in 2D culture or the 3DTEBM (all p values shown are <0.01; n = 3 samples examined over one independent experiment).
e P-selectin expression of ECs when incubated alone, with PBMCs, or MM (p value = 0.01; n = 3 samples examined over one independent experiment).
f Quantitative analysis and g qualitative images of tube-like formation on Matrigel (2D Culture) and the 3DTEBM with and without MM cells (all p values
shown are < 0.01; n = 27 cells examined over one independent experiment). Experiments seen here were repeated three times independently. All data
presented here are deﬁned as mean values +/− SD unless otherwise noted. Statistical signiﬁcance was analyzed using an unpaired Student’s two-sided
t-test (*p < 0.05).
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Fig. 2 PSGL-1 speciﬁcally binds to P-selectin. a Illustrations of non-targeted and P-selectin glycoprotein ligand-1 (PSGL-1)-targeted liposomes. b Cryogenic
transmission electron microscopy images of non-targeted and PSGL-1-targeted liposomes. c The binding rate of PSGL-1 to P-selectin assessed using
BIAcore. d Liposomal binding of PSGL-1-targeted and non-targeted particles to ECs in vitro (all p values shown are < 0.001; n = 3 samples examined over
one independent experiment). e Liposomal binding of PSGL-1-targeted and non-targeted particles to ECs in vivo (p value < 0.001; n = 4 samples examined
over one independent experiment). Experiments seen here were repeated three times independently. All data presented here are deﬁned as mean values
+/− SD. Statistical signiﬁcance was analyzed using an unpaired Student’s two-sided t-test (*p < 0.05).

injection (Fig. 3c). As expected, we found signiﬁcant accumulation in the spleen, kidney, and liver for both types of liposomes.
A signiﬁcantly higher presence of PSGL-1-liposomes was
detected in the blood and tumor compared to non-targeted.
We then assessed the accumulation of liposomes using
ﬂuorescence microscopy of histology sections of the tissues
which further conﬁrmed the preferential accumulation of the
PSGL-1-targeted liposomes in the tumor site compared to nontargeted (Fig. 3d).
4

Encapsulation of BTZ and Y27632 in liposomes. We loaded the
therapeutic (BTZ) and BMME-disrupting agents (Y27632) into
the lipid bilayer and hydrophilic core of the liposomes, respectively (Fig. 4a), and the physical characterization of the loaded
liposomes are shown in Supplementary Table 2. CryoTEM images of the loaded liposomes are seen in Fig. 4b. We developed
high-performance liquid chromatography (HPLC)-analysis
methods for both BTZ and Y27632 (Fig. 4c and d). We found that
BTZ and Y27632 had retention times of 2.1 and 4.1 min,
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Fig. 3 Targeting the tumor microenvironment with PSGL-1 in vivo. a Tumor accumulation of non-targeted (DiO) and PSGL-1-targeted (DiD) liposomes at
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here, each mouse represents an independent replicate. All data presented here are deﬁned as mean values +/− SD. Statistical signiﬁcance was analyzed
using an unpaired Student’s two-sided t-test or one-way analysis of variance (*p < 0.05).

respectively, with linear calibration curves in the range of
12.5–200 μg/ml and a linear correlation coefﬁcient of 0.99. We
then evaluated the encapsulation efﬁciency (EE) of the liposomes,
and found that the maximal EEs for BTZ and Y27632 were 77%
and 55%, respectively. In addition, we evaluated the drug release
of the encapsulated liposomes over time and found negligible
release of BTZ and 40% release of Y27632 over 48 h (Fig. 4e).
Effect of Y27632-loaded liposomes on adhesion signaling, MM
trans-endothelial migration in vitro, and MM extravasation
in vivo. We compared the effect of free and liposomal Y27632 on
adhesion signaling in MM cells and HUVECs. We found that
empty liposomes did not have an effect on adhesion signaling
when compared to untreated, while free Y27632 decreased
adhesion signaling as previously shown5. Liposomal Y27632
decreased adhesion (pSRC and pFAK) similarly to free Y27632 in

ECs. Interestingly, liposomal Y27632 decreased pFAK and pSRC
expression compared to untreated, empty liposomes, and free
Y27632 in MM cells (Fig. 5a, b). Quantitative assessments of the
data in Fig. 5a, b are shown in Supplementary Fig. 4a-d.
Functionally, both free and liposomal Y27632 reversed stromal
cell-derived factor (SDF)-induced trans-endothelial migration of
MM cells in vitro (Fig. 5c). Furthermore, the expression of Pselectin on HUVECs did not change with the exposure of Y27632
following a duration of 48 h (Fig. 5d). In vivo, non-targeted
Y27632-loaded liposomes resulted in mobilization of MM cells to
the blood circulation at 2, 4, and 24 h in a similar manner to free
drug. PSGL-1-targeted Y27632-loaded liposomes induced greater
mobilization of MM cells to the blood circulation at 2, 4, and 24
h, reﬂecting a greater inhibition of the MM–BMME interaction
than that of the free and non-targeted forms of Y27632 due to the
ability of targeting P-selectin (Fig. 5e).
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Fig. 4 Loading of BTZ and Y27632 into liposomes. a Schematic of PSGL-1 combination (BTZ and Y27632) nanoparticulate therapy. b Cryogenic
transmission electron microscopy images of BTZ and Y27632-encapsulated liposomes. c (i) HPLC calibration curve for BTZ. (ii) HPLC detection peak for
BTZ. d (i) HPLC calibration curve for Y27632. (ii) HPLC detection peak for Y27632. e Drug release of BTZ and Y27632 over a 48-h period. Experiments
seen here were repeated three times independently.

Effect of BTZ-loaded liposomes on survival, proliferation, and
apoptosis signaling in MM and HUVECs in vitro. We compared the effect of free and liposomal BTZ on apoptosis and
proliferation signaling in MM cells. While empty liposomes did
not have any effect on apoptosis and proliferation signaling, we
found that liposomal BTZ increased pro-apoptotic signaling
(cPARP, cCasp3, and cCasp9) and decreased proliferation (pRb,
pAKT, pS6R, and pERK) more profoundly compared to free BTZ
(Fig. 6a). Functionally, we found that liposomal BTZ killing of
MM cells was more effective than that of free BTZ in vitro, with
half-maximal inhibitory concentration (IC50) values of ~5 and
10 nM, respectively (Fig. 6bi). BTZ, in addition, did not affect the
survival of HUVECs (Fig. 6bii).
6

Effect of PSGL-1-targeted, BTZ- and Y27632-loaded liposomes
on MM tumor progression in vivo. To test the efﬁcacy of the
PSGL-1-targeted, BTZ- and Y27632-loaded liposomes on MM
tumor progression, we utilized 12 treatment groups of MMbearing mice: (i) vehicle, (ii) BTZ as a free drug, (iii) Y27632 as a
free drug, (iv) combination of BTZ and Y27632 as free drugs, (v)
non-targeted empty liposomes, vi) non-targeted BTZ-loaded
liposomes, (vii) non-targeted Y27632-loaded liposomes, (viii)
non-targeted multi-drug (BTZ and Y27632) liposomes, (ix)
PSGL-1-targeted empty liposomes, (x) PSGL-1-targeted BTZloaded liposomes, (xi) PSGL-1-targeted Y27632-loaded liposomes, and (xii) PSGL-1-targeted multi-drug (BTZ and Y27632)
liposomes.
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We found that the groups treated with non-targeted empty
liposomes and PSGL-1-targeted empty liposomes displayed
tumor growth rates similar to that of the vehicle-treated control
(Supplementary Fig. 5a). Y27632 as a free drug, in non-targeted
liposomes, or in PSGL-1-targeted liposomes also did not affect
tumor growth (Supplementary Fig. 5b). However, free BTZ
signiﬁcantly delayed tumor growth, and combining BTZ with
Y27632 only slightly enhanced this effect (Fig. 7ai); statistical
analyses of tumor efﬁcacy in Fig. 7 are shown in Supplementary
Table 3. Non-targeted BTZ-loaded liposomes signiﬁcantly
reduced tumor progression by approximately three orders of
magnitude when compared to non-targeted empty liposomes.
The non-targeted multi-drug (BTZ and Y27632) liposomes were
signiﬁcantly more effective than BTZ-loaded liposomes (Fig. 7aii).
Treatment with PSGL-1-targeted BTZ-loaded liposomes resulted
in a signiﬁcant reduction in tumor progression (approximately
three orders of magnitude) compared to non-targeted empty
liposome controls; PSGL-1-targeted multi-drug liposomes signiﬁcantly improved the antitumor effect and reduced tumor
progression by an order of magnitude compared to the PSGL-1-

targeted BTZ-loaded liposomes (Fig. 7aiii). Compared to free
BTZ, the non-targeted and PSGL-1-targeted liposomal BTZ
formulations resulted in a signiﬁcant decrease in tumor
progression (Supplementary Fig. 5c); statistical analyses of
Supplementary Fig. 4 are shown in Supplementary Table 4. The
combination of BTZ and Y27632 was more effective than BTZ
alone in only the liposomal formulations (non-targeted and
PSGL-1-targeted). The group treated with PSGL-1-targeted
multi-drug liposomes displayed the greatest reduction in tumor
progression 35 days after treatment when compared to the other
11 treatment groups (Supplementary Fig. 5d).
In addition to tumor progression, we also assessed the survival
of MM-bearing mice treated with the various treatments
described above. We found that the mice treated with nontargeted empty liposomes and PSGL-1-targeted empty liposomes
died around the same time as the vehicle-treated controls
(Supplementary Fig. 6a). In addition, Y27632 alone as a free
drug, in non-targeted liposomes, or in PSGL-1-targeted liposomes
did not extend the survival of the MM-bearing mice (Supplementary Fig. 6b). Free BTZ signiﬁcantly prolonged the survival of
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~30% (PSGL-1-targeted BTZ-only liposomes) to 60% (Fig. 7biii).
Non-targeted BTZ-loaded liposomes extended the survival of
MM-bearing mice, an effect that was signiﬁcantly enhanced when
treated with PSGL-1-targeted BTZ liposomes (Supplementary
Fig. 6c); statistical analyses of Supplementary Figs. 5 and 6 are
shown in Supplementary Table 4. The combination of BTZ and
Y27632 prolonged survival in the non-targeted and PSGL-1targeted formulations compared to free BTZ and Y27632
(Supplementary Fig. 6d). Moreover, targeting P-selectin with
PSGL-1-targeted liposomes prolonged the survival of BTZ and
multi-drug groups of mice.
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Fig. 6 BTZ induces apoptosis only in MM. a Immunoblotting of factors
related to apoptosis (cPARP, p21, cCasp3, and cCasp9), cell cycle (pRB),
and survival (pAKT, pS6R, and pERK) following treatment with empty
liposomes, liposomal BTZ, or free BTZ. b (i) Viability of MM cells following
a 24-h incubation with increasing concentrations of BTZ. (ii) Viability of
ECs following a 24-h incubation with increasing concentrations of BTZ.
Experiments seen here were repeated three times independently. All data
presented here are deﬁned as mean values +/− SD.

the mice compared to untreated; however, this effect was not
improved when BTZ was combined with Y27632 (Fig. 7bi);
statistical analyses of survival curves in Fig. 7 are shown in
Supplementary Table 3. Mice treated with non-targeted BTZloaded liposomes lived signiﬁcantly longer than mice treated with
vehicle or Y27632-loaded liposomes, and non-targeted multidrug liposomes signiﬁcantly improved the rate of survival past
50 days from 0% (BTZ-only liposomes) to 14% (Fig. 7bii). PSGL1-targeted BTZ-loaded liposomes signiﬁcantly extended the
survival of the mice when compared to the PSGL-1-targeted
empty and Y27632-loaded liposomes, and PSGL-1-targeted
multi-drug liposomes slightly increased the survival rate from
8

Effect of PSGL-1-targeted, BTZ-, and Y27632-loaded liposomes on BTZ-associated side effects in vivo. In parallel with
the above experiments, we also assessed the occurrence and
severity of BTZ-associated side effects in the treatment groups. As
expected, the free-drug treatments induced signiﬁcant weight loss,
whereas the non-targeted and PSGL-1-targeted treatments
resulted in signiﬁcantly reduced weight loss compared to the freedrug regimen. Notably, the weights of the mice treated with the
PSGL-1-targeted treatments actually increased by ~5% compared
to their weights measured prior to therapy (Fig. 7c). The nontargeted forms of treatment decreased hair loss compared to the
free drug, and the use of PSGL-1-targeted liposomes resulted in
absolutely no hair loss (Fig. 7d).
Discussion
Drug resistance and dose-limiting toxicities remain signiﬁcant
barriers for the treatment of MM and cancer in general. The
BMME directly interacts with MM cells and induces pleiotropic
signaling that confers tumorigenesis and drug resistance in MM
cells16. BTZ is the ﬁrst FDA-approved PI and one of the frontline
regimens used for the treatment of MM17. Despite the clinical
success of BTZ in the past two decades, its dose-limiting toxicities
and the development of drug resistance hinder its ability to fully
eradicate MM18. Thus, approaches to improve the efﬁcacy and
reduce the toxicity of promising treatments such as BTZ are
urgently needed.
One potential approach to improve the efﬁcacy and reduce the
toxicity of treatment is to encapsulate the PI in a nanoparticle and
add targeting elements which will increase the speciﬁc accumulation of the particle (and the PI within) to the tumor13,19. We
previously demonstrated that BTZ loaded into a chitosan nanoparticle and decorated with anti-CD38 antibodies improved the
accumulation of BTZ in MM cells, which overexpress CD38, and
reduced the toxicity of BTZ in normal tissue14. However, several
studies have shown that the ﬁrst tissue barrier nanoparticles face
are ECs in the blood vessels adjacent to the tumor rather than the
tumor cells themselves13,19. Therefore, in this study, we aimed to
target the tumor-associated endothelium as a unique target in the
tumor area.
We previously demonstrated that PSGL-1 (the natural ligand of
P-selectin) plays a critical role in the interaction of MM cells with
ECs and is involved in MM cell adhesion and homing to the
BM7,9. Therefore, in this study, we hypothesized that the receptor
of PSGL-1 (P-selectin) is highly and speciﬁcally expressed on the
endothelium in the vicinity of MM cells, which can be used as a
unique target for speciﬁc drug delivery to the tumor area. We
found that P-selectin expression was highly upregulated on MMassociated endothelium compared to healthy endothelium in MM
patients, MM-bearing mice, and 3DTEBM cultures in vitro
(Fig. 1). Notably, P-selectin overexpression was not observed in
classic 2D co-cultures of MM cells and ECs, but was overexpressed
in ECs in the 3DTEBM, a model which we further utilized for
binding assays. We found that PSGL-1-targeted liposomes
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Fig. 7 PSGL-1 combination nanoparticle therapy decreased tumor burden, prolonged survival, and reduced adverse events in vivo. a MM burden of
mice treated with (i) free, (ii) non-targeted, and (iii) PSGL-1-targeted forms of treatment (vehicle, Y27632, BTZ, and Y27632 + BTZ) measured using
bioluminescence. Data presented here are deﬁned as mean values +/−SEM. b Survival of mice treated with (i) free, (ii) non-targeted, and (iii) PSGL-1targeted drugs. c Percent weight change of mice in each group; each group was stratiﬁed by the form of treatment injected (all p values shown are <0.05;
n = 3, n = 7, and n = 6 samples examined over one independent experiment for the groups: free, non-targeted, and PSGL-1-targeted, respectively). Data
presented here are deﬁned as mean values +/−SD. d Representative images of hair loss experienced in vivo following BTZ and combination treatments
(free, non-targeted, and PSGL-1-targeted). For the experiments seen here, each mouse represents an independent replicate. Statistical signiﬁcance was
analyzed using an unpaired Student’s two-sided t-test (*p < 0.05).

speciﬁcally bound to MM-associated endothelium compared to
normal endothelium in vitro and in vivo (Figs. 2 and 3). These
results agree with previous observations of P-selectin overexpression in tumor-associated endothelium in glioblastoma,
lung, ovarian, lymphoma, breast, and other cancer subtypes20,21,
which suggests that PSGL-1 could be used to target the tumorassociated endothelium in other cancer subtypes.
The limitations of cancer therapy not only include lack of
speciﬁcity but also the development of drug resistance over time.

For instance, we previously demonstrated that the interaction
between MM cells and their BMME plays a crucial role in the
development of resistance to therapy5–8. We demonstrated that
using a BMME-disrupting agent, such as the CXCR4 inhibitor
AMD3100, re-sensitized MM cells to BTZ in vivo8. The combination treatment containing AMD3100 (Plerixafor) and BTZ was
also translated to a clinical trial (NCT00903968) where an
encouraging 48.5% overall response rate in relapsed or refractory
MM patients was observed22. However, following completion of
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this trial, multiple issues remained that hinder a physician’s
ability to routinely prescribe Plerixafor to MM patients. First,
Plerixafor has a pharmacokinetic (PK) half-life between 3 and 5
h23, which severely hinders efﬁcient drug administration, as the
drug needed to be infused for 6 consecutive days, resulting in
signiﬁcant discomfort to the participating patients. Second, the
PK half-life of Plerixafor is signiﬁcantly shorter than the half-life
of BTZ [40 h24], which hinders determination of an effective
combinatorial and synchronized treatment schedule. Third, the
Plerixafor and BTZ combination treatment induced various
adverse side effects, such as sensory neuropathy, to the participants in the clinical study. Hence, we hypothesized that a
nanoparticulate delivery system with dual loading of chemotherapy and a BMME-disrupting agent will overcome the
mentioned PK issues and ensure simultaneous delivery of the two
agents to the desired target.
To test this hypothesis, we combined BTZ with a BMMEdisrupting agent, a ROCK inhibitor, into liposomes. We used the
ROCK inhibitor in place of Plerixafor in this formulation because
Plerixafor is a CXCR4 inhibitor and needs to be released in the
extracellular milieu to inhibit the extracellular domain of CXCR4;
while BTZ needs to be internalized into the cell to inhibit the
proteasome. The two drugs’ different sites of action and release
kinetics would present signiﬁcant challenges in their dual delivery. Therefore, we paired BTZ with a ROCK inhibitor that acts as
a BMME-disrupting agent and targets an intracellular kinase. We
have previously shown that this compound inhibits the interaction between MM cells and their BMME, similar to Plerixafor5.
The ROCK inhibitor, Y27632, was loaded to the aqueous core
of the liposomes, while BTZ was loaded to the lipid bilayer
(Fig. 4). We found that liposomal Y27632 downregulated adhesion signaling (SRC and FAK) in MM and BMME cells in vitro,
reduced trans-endothelial migration of MM cells in vitro, and
increased mobilization of MM cells in vivo; the effect of liposomal
Y27632 was similar to or greater than that of free Y27632 (Fig. 5).
Similarly, we found that liposomal BTZ downregulated proliferation signaling, increased apoptosis signaling, and induced
cytotoxicity in MM cells, but not in ECs in vitro, which is consistent with previously published ﬁndings25. On the other hand,
there are published studies that have seen a decrease in viability
and inhibition of cellular growth of ECs when treated with BTZ;
however, these studies observe cell death when the concentration
of BTZ reaches 100 nM to 1 μM26. In addition, the effect of
liposomal BTZ was similar to or greater than that of free BTZ
(Fig. 6).
We then assessed the efﬁcacy of the targeted combination
therapy of BTZ and Y27632 in MM-bearing mice in vivo. We
found that combining a PI with a BMME-disrupting agent was a
successful approach to increase MM sensitivity to therapy and
overcome BMME-induced drug resistance in the liposomal forms
of delivery (non-targeted liposomes and PSGL-1 targeted liposomes). In the PSGL-1-targeted formulation, the combination of
BTZ with Y27632 resulted in a signiﬁcantly better tumor efﬁcacy
and survival compared to all other treatment groups (Fig. 7).
Compared to administration as a free drug, delivery of BTZ
with liposomes improved the therapeutic efﬁcacy of BTZ alone or
in combination with Y27632; this result is likely due to speciﬁc
accumulation of the drugs in the tumor due to the EPR effect of
liposomes13. However, the use of PSGL-1-targeted liposomes
further increased the speciﬁcity and therapeutic efﬁcacy of BTZ
when combined with Y27632 due to their speciﬁc interaction with
the MM-associated endothelium.
No difference was found between PSGL-1-targeted and nontargeted liposomal BTZ. We hypothesize that this is due to the
fact that BTZ did not have a signiﬁcant killing effect on ECs
themselves (as shown in Fig. 6bii); therefore, the effect was mainly
10

due to the passive (EPR effect) accumulation in the tumor, and
further targeting to ECs will not create an additional effect. In
contrast, the PSGL-1-targeted multi-drug combination had a
better effect than the non-targeted multi-drug formulation
(Supplementary Fig. 5d). We hypothesize that this is due to the
direct effect of the ROCK inhibitor on the ECs, which in turn
disrupted their interaction with MM cells and made the MM cells
more sensitive to BTZ (which accumulated in the tumor area by
passive EPR effect and/or by active targeting to the tumorassociated endothelium).
The combinatorial effect of BTZ and Y27632 was more dramatic in the liposomal formulations than as free drugs due to
their synchronized delivery, and the effect was even more pronounced in the PSGL-1-targeted liposomes. Furthermore, PSGL1-targeted liposomes reduced the side effects of BTZ; these
liposomes did not cause weight or hair loss when compared to the
non-targeted liposomes and free drugs (Fig. 7).
In conclusion, PSGL-1-targeted, BTZ- and Y27632-loaded
liposomes, which target the MM-associated endothelium and
synchronize the delivery of PI with BMME-disrupting agents,
demonstrated improved speciﬁcity and efﬁcacy and reduced the
side effects when compared to free drugs and non-targeted
liposomes. These results support the use of PSGL-1-targeted
multi-drug and even non-targeted liposomal BTZ formulations
for the enhancement of patient outcome in MM.
Methods
Materials and reagents. The phospholipids, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-mPEG2000), and 1,2-distearoyl-sn-glycero3-phosphoethanolamine-N-[succinyl(polyethylene glycol)-2000] (DSPE-PEG
(2000)-succinyl) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).
Cholesterol (Chol), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), and N-Hydroxysuccinimide (NHS) were purchased from SigmaAldrich (St. Louis, MO, USA). Calcein violet and lipophilic tracers (DiO and DiD)
were purchased from Invitrogen (Eugene, OR). BTZ and Y27632 were purchased
from MedKoo Biosciences (Morrisville, NC). Recombinant PSGL-1 protein was
purchased from Novoprotein (Summit, NJ). Monoclonal antibodies (mAb) used
for immunoblots were purchased from Cell Signaling Technology (Danvers, MA).
Phospho-Akt (pAKT; #4060), phospho-Erk1/2 (pERK; #4370), phospho-Rb (pRB;
#9308), p21 (#2947), cleaved Caspase3 (cCasp3; #9664), cleaved Caspase 9 (cCasp9;
#7237), cleaved PARP (cPARP; #5625), phospho-FAK (pFAK; #3284), phosphoSRC (pSRC; #6943), and phospho-S6 ribosomal protein (pS6R; #4858) were all
used at a dilution of 1:1000. α-Tubulin (#2125) was used as a loading control at a
dilution of 1:3000. The immunoblots were detected using an ECL Plus chemiluminescent system (PerkinElmer, Waltham, MA). The mAbs used for ﬂow cytometry were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany) unless
otherwise noted.
Cell culture. The MM cell lines, MM.1S and H929, were purchased from the
American Type Culture Collection (ATCC, Rockville, MD), OPM-2 and green
ﬂuorescent protein-labeled and luciferase-transfected MM.1S (MM.1S-GFP-Luc)
were a kind gift from Dr. Irene Ghobrial (Dana-Farber Cancer Institute, Harvard
Medical School, Boston, MA). Human umbilical vein endothelial cells (HUVECs)
were purchased from Angio-Proteomie (Boston, MA). Human samples for this
study were collected under informed consent, in concordance with Washington
University Institutional Review Board (IRB) approval (IRB protocol number
201102270). MM cell lines were cultured in RPMI-1640 media (Corning, Tewksbury, MA) supplemented with 10% fetal bovine serum (FBS; Gibco, Life Technologies, Grand Island, NY), 2 mmol/L L-glutamine, 100 μg/mL penicillin, and 100
μg/mL streptomycin (Corning CellGro). HUVECs were cultured in Endothelial
Growth Medium (EGM, Angio-Proteomie, Boston, MA) supplemented with
endothelial growth supplements (including 10% FBS, recombinant growth factors,
and 1% penicillin and streptomycin). All cells were cultured at 37 °C and in 5%
CO2 in a NuAire water jacket incubator (Plymouth, MN).
Expression of P-selectin in MM-associated ECs in human samples. BMMNCs
from healthy (n = 6) and MM patients (n = 6) were washed with PBS and stained
with anti-human CD45 (REA747), CD31 (REA730), VEGFR-2 (REA1046), and
CD62P (REA389) mAbs or their respective isotype controls for 1 h. Cells were
washed and analyzed by ﬂow cytometry. First, we gated CD45-negative cells to
exclude the leukocytes. Then from that population, we gated the ECs as CD31
+/VEGFR-2+ double-positive cells. ECs were analyzed then for the expression of
P-selectin (CD62P) as the ratio of the mean ﬂuorescence intensity (MFI) of CD62P
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divided by the isotype control (RMFI). Then the RMFI values of P-selectin
expression on ECs in MM patients were divided by the values acquired from the
healthy donor samples27. Flow cytometry ﬁles were analyzed using MACSQuantify
and FlowJo.
Expression of P-selectin in ECs in vivo. All animal work presented in this study
was approved by the Institutional Animal Care and Use Committee at Washington
University School of Medicine in St. Louis. The mice used were NCG male 50–56day-old mice (Charles River, Wilmington, MA) unless otherwise stated. MM.1S
cells (2 × 106 cells/mouse) were injected intravenously into ﬁve mice and tumor
progression was conﬁrmed using bioluminescent imaging (BLI) at 4 weeks postinjection. Five healthy mice were used as well to assess P-selectin expression. Mice
were sacriﬁced and femurs were crushed and washed with PBS for the collection of
BMMNCs. The cells were stained with CD45 (REA737), CD31 (390), VEGFR-2
(REA1116), and CD62P (REA344) murine mAbs or their respective isotype controls for 1 h. Cells were washed and analyzed by ﬂow cytometry. ECs were gated as
CD31 and VEGFR-2 positive cells. Then the RMFI values of P-selectin expression
on ECs in MM-bearing mice were divided by the values acquired from the
healthy mice.
For immunoﬂuorescence, MM.1 S cells (2 × 106 cells/mouse) were injected
intravenously into three mice and tumor progression was conﬁrmed using BLI at
4 weeks post-injection. Three healthy mice were used as well to assess VEGFR-2
and P-selectin expression. Mice were sacriﬁced; femurs were processed and
embedded in parafﬁn28. Brieﬂy, the processed slides were heated at 55 °C overnight
to remove the parafﬁn and incubated in xylene twice for 5 min. To rehydrate the
tissue, the slides were put into 100% ethanol twice for 3 min. Then 95% ethanol
twice for 3 min and 80% ethanol twice for 3 min. The slides were then washed in
PBS for 5 min and soaked in double-distilled water for 30 min. Antigen retrieval
process was started by inserting 800 μL of unmasking solution (Vector Labs,
Burlingame, CA) into 80 mL of double-distilled water. The slides were put into this
solution, put into a pressure cooker, and microwaved on high for 8 min and
medium for 3 min. The slides were set to cool in an unmasking solution for 20 min
and washed in PBS for 5 min. The slides were then blocked with 120 mL of PBS
supplemented with 0.3% Triton-x, 5% goat serum, and 5% FBS for 2 h at room
temperature. Following blocking, we washed with PBS for 5 min and incubated the
slides in the primary antibodies (VEGFR-2 (REA1116), and CD62P (RB40.34; BD
Biosciences, San Jose, CA)) diluted in PBS supplemented with 3% bovine serum
albumin. Each antibody concentration was ten micrograms per milliliter. The slides
were incubated with the antibodies overnight in 4 °C. PBS was used to wash the
slides three times for 5 min. A coverslip was then added with mounting medium
for imaging. For imaging, we used an Olympus BX51 ﬂuorescent microscope at Ex/
em 365/420 and 620/670 nm.
Tube-like formation of ECs on 2D Matrigel and 3DTEBM. On the ﬁrst day, DiOlabeled MM cells (3 × 104 cells/well) were cultured in regular 96-well plates (2D) or
in the 3DTEBM15. To make the 3DTEBM, 40 µL of BM plasma was added to 60 µL
RPMI-1640 complete medium with a ﬁnal concentration of 1 and 4 mg/mL calcium chloride and tranexamic acid, respectively. On the next day, Matrigel was
added on top of the 3DTEBM, or to the regular 96-well, as a control (2D).
HUVECs were stained with DiD and plated on top of the Matrigel for all well
conditions (2D and 3DTEBM; 3 × 104 cells/well), in RPMI-1640 media without
serum. The samples were imaged via ZEN 2009 using a ﬂuorescent microscope 4 h
post-addition of the HUVECs. Tube length was measured using ImageJ.
Expression of P-selectin in ECs cultured with cell lines in vitro. The expression
of P-selectin in vitro was evaluated in HUVECs using two models. (i) In the 2D
tissue culture model, HUVECs (1 × 104 cells pre-labeled with DiO) and MSP-1
stromal cells (1 × 104 cells) were co-cultured with or without MM cell lines
(MM.1S, H929, or OPM-2; 3 × 104 cells) per well in a 96-well plate. (ii) In the
3DTEBM model, MSP-1 stromal cells (1 × 104 cells) with or without MM cell lines
(MM.1S, H929, or OPM-2; 3 × 104 cells) were suspended in BM plasma and set to
solidify into a 3DTEBM matrix. After 2 h, Matrigel (Corning, Tewksbury, MA) was
added on top of the scaffold, and HUVECs (1 × 104 cells pre-labeled with DiO)
were added on top of the Matrigel with non-supplemented EGM media. HUVECs
and stromal cells with and without MM cells were cultured in 2D and 3DTEBM
models for 24 h. Then, the cultures were digested with collagenase, and cells were
retrieved for ﬂow cytometry analysis. The experiment was independently repeated
three times with ﬁve replicates each.
To determine that the increase in P-selectin expression on ECs was speciﬁcally
associated with the presence of MM, we co-cultured ECs with MM cells or normal
peripheral blood mononuclear cells (PBMCs; 3 × 104 cells/well) extracted from
healthy donors, in the 3DTEBM following the procedure described above. For the
effect of Y27632 on the expression of P-selectin, HUVECs were plated on the
3DTEBM containing MM and treated with free Y27632 (25 μM) for 24 and 48 h
and analyzed for P-selectin expression via ﬂow cytometry.
Confocal imaging of 3DTEBM cultures of HUVECs. MSP-1 stromal cells (1 × 104
cells pre-labeled with DiD) and MM.1S cells (3 × 104 cells pre-labeled with DiO)
were suspended in BM plasma to form a 3D scaffold in a Nunc Lab-Tek II
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Chamber Slide System (Thermo Fisher, Waltham, MA). After 2 h, Matrigel was
added on top of the scaffold and HUVECs (1 × 104 cells pre-labeled with calcein
violet) were subsequently added on top of the Matrigel. The HUVECs, stromal
cells, and MM cells were cultured in the 3DTEBM for 24 h. Samples were then
imaged using a FV1000 confocal microscope with an XLUMPLFLN 20XW/1.0
immersion objective lens (Olympus, Central Valley, PA) (excitation/emission: 405/
450 ± 20 (calcein violet), 488/ 520 ± 20 (DiO), and 633/650 + (DiD) nm).
Preparation and characterization of liposomes. Liposomes were prepared using
the thin layer evaporation method29. Brieﬂy, lipids (DPPC, Chol, DSPEmPEG2000, and DSPE-PEG(2000)-succinyl at a molar ratio of 6:3:0.5:0.5) were
dissolved in a chloroform/methanol mixture (3:1, v/v) and the solvent was then
evaporated through a rotary evaporator (Heidolph, Schwabach, Germany) to form
a thin lipid ﬁlm. The ﬁlm was then hydrated with PBS and extruded with an
extruder set (Avanti Polar Lipids). Fluorescent liposomes were prepared by dissolving DiD in the organic solvent with the lipids (before ﬁlm formation).
Conjugation of PSGL-1 to the surface of liposomes was performed by using
carbodiimide chemistry. Brieﬂy, the liposomes were suspended in a solution of
0.25 M EDC and 0.25 M NHS (in water) and incubated for 10 min at room
temperature. Then, PSGL-1 was added to the mixture and the colloidal suspension
was incubated at 4 °C overnight in a light-protected environment with gentlestirring. Unbound protein was removed using Amicon Ultra Centrifugal Filter
Units (100 kDa MWCO). The mean sizes, polydispersity index (PDI) and zetapotential (ZP) were analyzed by dynamic light scattering (DLS) analysis using a
Zetasizer Nano ZS (Malvern, Malvern, UK).
Cryogenic transmission electron microscopy imaging of liposomes. Samples
were prepared on Quantifoil holey carbon grids (R2/2 300 mesh copper) and
plunge frozen using a Vitrobot Mark IV (Thermo Fisher) which was set to 4 °C and
100% humidity. Three microliters of sample was applied to the Quantifoil grids,
blotted to remove excess ﬂuid, and plunge frozen into liquid ethane. Grids were
then stored in liquid nitrogen until imaged. Vitriﬁed grids were imaged using a
JEM-1400 TEM (JEOL, Peabody, MA) operating at 120 kV, equipped with a
626 single tilt liquid nitrogen cryo-transfer holder (Gatan, Pleasanton, CA) and a
XR111 CCD camera (Advanced Microscopy Techniques, Woburn, MA). The
sample holder was kept at −175 °C during imaging to prevent devitriﬁcation. All
images were acquired using a nominal magniﬁcation of ×25,000 corresponding to a
pixel size of 7.38 Å/pixel.
Measurement of the afﬁnity of PSGL-1-targeted liposomes for P-selectin by
surface plasmon resonance. The afﬁnity of PSGL-1-targeted liposomes for Pselectin was measured by the biosensor-based surface plasmon resonance (SPR)
technique using an automatic apparatus BIAcore T200 (GE Healthcare, Chicago,
IL). Recombinant P-selectin protein was immobilized using carbodiimide chemistry on the CM4 sensor chip surface (ligand), and PSGL-1-targeted and nontargeted liposomes were used as the analyte.
Binding of PSGL-1-targeted liposomes to ECs in vitro. HUVECs (pre-labeled
with DiO) were grown on top of the 3DTEBM as described above. DiD-labeled
non-targeted or PSGL-1-targeted liposomes were cultured with the HUVECs for 2
h. The 3D cultures were then digested, washed, and analyzed via ﬂow cytometry.
The experiment was independently repeated three times with ﬁve replicates each.
Binding of PSGL-1-targeted liposomes to ECs in vivo. MM.1 S cells (2 × 106
cells/mouse) were injected intravenously into ten mice and tumor progression was
conﬁrmed using BLI at 4 weeks post-injection. Mice were then injected intravenously with DiD-labeled non-targeted or PSGL-1-targeted liposomes (2 mg/mL of
lipids; 5 mice per group). Mice were sacriﬁced and femurs were ﬂushed with PBS
and crushed. The cells were stained with CD45 (REA737), CD31 (390), and
VEGFR-2 (REA1116) murine mAbs or their respective isotype controls for 1 h.
Cells were washed and analyzed by ﬂow cytometry. ECs were gated as CD31 and
VEGFR-2 positive cells. Then the MFI values of the PSGL-1-targeted liposomes
bound to ECs in mice were divided by the values obtained from the non-targeted
samples.
Fluorescent imaging of tumor in vivo and organs ex vivo. Four NSG mice
(shaven) were injected intravenously with non-targeted and PSGL-1-targeted
liposomes that were stained with DiO and DiD, respectively. These mice were
imaged at t = 0.1, 1, 4, and 24 h using the In-Vivo MS FX PRO ﬂuorescent imaging
system (Bruker, Billerica, MA) at Ex/em of 460/535 and 620/670 nm. Following 24
h, the tissues were extracted from each mouse and imaged in the In-Vivo MS FX
PRO ﬂuorescent Bruker imaging system.
Histological assessments of tissue. Following ex vivo imaging, tissues were
frozen in OCT (Tissue Tek, Torrance, CA), sliced using a Cryocut 1800 (Leica,
Wetzlar, Germany), and imaged using an Olympus BX51 ﬂuorescent microscope at
Ex/em 460/535 and 620/670 nm. No staining was used due to the ﬂuorescence of
the liposomes.
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High-performance liquid chromatography for detection of BTZ and Y27632.
BTZ and Y27632 were analyzed using high-performance liquid chromatography
(HPLC, Agilent 1100 series, Santa Clara, CA) with a reverse phase C-18 column
(Agilent Zorbax Eclipse XDB-C18, 4.6 mm × 150 mm).
For detection of BTZ, a 50% acetonitrile solution in water containing 0.1%
triﬂuoroacetic acid (TFA) was used as the mobile phase at a ﬂow rate of 1 mL/min,
as reported previously14. A calibration curve was obtained by plotting the area
under the curve (AUC) of the BTZ HPLC peak (at retention time = 2.2 min, λ =
270 nm) for a concentration range of 0–200 μg/mL.
For detection of Y27632, a gradient of acetonitrile/water containing 0.1% TFA
was used as the mobile phase at a ﬂow rate of 1 mL/min30. The percent of
acetonitrile in the mobile phase was 0% (at 0–3 min), then decreased gradually to
33% water (3–3.5 min), and decreased gradually back to 0% (3.5–7 min). A
calibration curve was obtained by plotting the AUC of the Y27632 HPLC peak (at
retention time = 4 min, λ = 260 nm) for a concentration range of 0–200 μg/mL. All
HPLC data were analyzed via OpenLab.
Drug release and evaluation of drug entrapment efﬁciency. Each drug was
encapsulated in a separate liposome formulation followed by centrifugation
(130,000 rcf at 4 °C for 1 h) to remove any free drug and re-suspended in fresh PBS.
BTZ liposomes were put into dialysis bags (3.5 kD; Spectrum Labs, Rancho
Dominguez, CA); the supernatant was taken for each time point (t = 1, 3, 6, 12, 24,
48) and analyzed using the HPLC methods mentioned above.
To evaluate loading efﬁciency, liposomes were centrifuged at 130,000 rcf at 4 °C
for 1 h using a Beckman Optima™ XPN ultracentrifuge equipped with a SW 50.1
ﬁxed angle rotor (Beckman Coulter Inc., Fullerton, CA, USA). The amount of BTZ
and Y27632 in the supernatant was evaluated by HPLC. The entrapment efﬁciency
(EE) was calculated according to the following equation:
EE ¼ DT  DU =DT ´ 100

ð1Þ

where DT is the total amount of drug added to the formulation during the
preparation, and DU is the amount of unincorporated drug found in the
supernatant.
Effect of free and liposomal Y27632 on trans-endothelial migration of MM
cells in vitro. Trans-endothelial migration5 was performed by incubating HUVECs
(5 × 103 cells) overnight in the upper chamber of a Boyden chamber (Corning)
prior to adhesion assay. MM.1S cells were pre-treated with (or without) free
Y27632 (25 μM) or liposomal Y27632 (25 μM equivalent) for 3 h. Cells were then
placed in the upper migration chamber in the presence or absence of 30 nM SDF-1
in the lower chamber. After 3 h of incubation, cells that migrated to the lower
chambers were counted by ﬂow cytometry.
Effect of free and liposomal Y27632 on mobilization of MM cells to the
circulation in vivo. MM.1S-GFP-Luc cells (2 × 106 cells/mouse) were injected
intravenously into nine mice, and tumor progression was conﬁrmed using BLI at
4 weeks post-injection. Mice were treated with intravenous injections of (i) free
Y27632 (2.5 mg/kg, n = 3); (ii) Y27632-loaded non-targeted liposomes (2.5 mg/kg
equivalent, n = 3); and (iii) Y27632-loaded PSGL-1-targeted liposomes (2.5 mg/kg,
n = 3). Blood was collected from the tail vein of each mouse at 0 (before), 2, 4, and
24 h after injection. Blood samples were lysed with 1X red blood cell lysis buffer
(BioLegend, San Diego, CA) using the manufacturer’s instructions and PBMCs
were analyzed via ﬂow cytometry.

Chemiluminescent Kit (Thermo Fisher). Blots were imaged on a ChemiDoc XRS
imaging system via Bio-Rad Image Lab (Bio-Rad).
Effect of free and liposomal BTZ on MM and EC viability in vitro. DiD-labeled
HUVECs and DiO-labeled MM.1S cells were co-cultured overnight and treated
with vehicle (control), free BTZ (0–50 nM), empty liposomes, or liposomal Y27632
(0–50 nM equivalent) for 24 h, and the survival of MM and HUVECs was analyzed
via ﬂow cytometry. MM cells were gated as DiO+ cells and HUVECs were gated as
DiD+ cells, and each cell population was counted and normalized against counting
beads (Invitrogen). Survival was calculated as the percent of vehicle-treated
controls.
Efﬁcacy of BTZ and Y27632-loaded PSGL-1-targeted liposomes on MM tumor
progression in vivo. MM.1S-GFP-Luc cells (2 × 106 cells/mouse) were injected
intravenously into 84 mice, and tumor progression was conﬁrmed using BLI at
3 weeks post-injection (average photon ﬂux of 2.5E07 photons per second). Mice
were randomized into 12 groups of 7 mice each, which received weekly intravenous
injections of (i) saline, (ii) Y27632 as a free drug (2.5 mg/kg), (iii) BTZ as a free
drug (1 mg/kg), (iv) a combination of free BTZ and free Y27632, (v) empty nontargeted liposomes, (vi) non-targeted liposomal Y27632 (2.5 mg/kg equivalent),
(vii) non-targeted liposomal BTZ (1 mg/kg), (viii) non-targeted liposomal combination of BTZ and Y27632 in the same liposome (2.5 mg/kg and 1 mg/kg,
respectively), (ix) empty PSGL-1-targeted liposomes, (x) PSGL-1-targeted liposomal Y27632 (2.5 mg/kg), (xi) PSGL-1-targeted liposomal BTZ (1 mg/kg), and (xii)
PSGL-1-targeted liposomal combination of BTZ and Y27632 in the same liposome
(2.5 mg/kg and 1 mg/kg, respectively). Tumor progression was assessed weekly by
BLI. Weight was recorded twice per week, and the survival and general health of
the mice were recorded daily.
Statistical analyses. All data from in vitro and in vivo experiments were expressed
as means ± standard deviation. Statistical signiﬁcance was analyzed using a Student’s t-test or two-way analysis of variance (ANOVA). Log-rank test was used to
compare the Kaplan–Meier curves. P values <0.05 were used to indicate statistically
signiﬁcant differences. All graphs were plotted on Microsoft Excel and
GraphPad Prism.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Source data are included in the supplementary. All data ﬁles generated are available upon
request. Source data are provided with this paper.
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